ClinicalTrials.gg
CompletedNCT01225640Updated Jan 14, 2016

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

A Phase 2 interventional study of PNU-100480 and PNU-100480 in Tuberculosis, sponsored by Sequella, Inc.. Completed at 2 sites in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-01-14.

Sponsored by Sequella, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 210 studies in Tuberculosis with a site in South Africa — 21 open to participants now, 35 under way, 8 of them phase 3. Tuberculosis · South Africa.

Enrollment
140th of 176
59 · median 214
Started
2011
with 4 others
Phase 2
67 of 210
6 open now
Registered
42nd of 210
by date

Among the 210 studies in Tuberculosis with a site in South Africa, this one is the 140th largest by enrollment of the 176 interventional ones that give a count, is one of 5 that started in 2011, is one of 67 in phase 2, and was the 42nd registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

21 of the 210 studies in Tuberculosis with a site in South Africa are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Tuberculosis with a site in South Africa, or all of them as a file.
02

Study summary

PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Tuberculosis
  • EBA
  • WBA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males or females between 18 and 65 years; women of must be willing to adhere to lifestyle requirements regarding /pregnancy prevention.
  • Newly diagnosed sputum smear-positive pulmonary TB confirmed with acid-fast bacillus (AFB) smear and chest x-ray. Patients with TB more than 5 years ago who completed treatment, are healthy, and meet other inclusion criteria may be included.
  • Body weight between 40 and 90 kg, inclusive (in light clothing, no shoes).
  • Reasonably normal (>=8 gm/dL), renal function (serum creatinine \<2 mg/dL), hepatic function (serum \<3xULN and total \<1.3 mg/dL), and random glucose \<150 mg/dL.

Exclusion criteria

Exclusion Criteria:

  • infection with helper/inducer T-lymphocytes (CD4 cell) count of \<=350x10-6/L.
  • Presence of significant hemoptysis. Subjects who cough up frank blood (more than blood streaked sputum) will not be eligible.
  • Pregnant or nursing females; females of unwilling or unable to adhere to guidelines.
  • Significant respiratory impairment (respiratory rate >35/minute).
  • Clinical suspicion of disseminated TB or tuberculosis meningitis.
  • Subjects with diabetes mellitus on insulin and/or who have poorly controlled disease.
  • Subjects with confirmed or suspected multi-drug resistant TB.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    PNU-100480 600 mg BID

    Drug: PNU-100480

  • Experimental
    PNU-100480 1200 mg QD

    Drug: PNU-100480

  • Active comparator
    RHZE

    conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally

    Drug: RHZE

Interventions

  • 600 mg twice daily (BID) for 14 days

  • 1200 mg once daily (QD) for 14 days

  • DrugRHZE

    Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)

    Also known as: Rifafour, Rimstar

06

What researchers measure

Primary outcomes

  1. The primary endpoint is rate of change in sputum log CFU/mL count (EBA) from Days 0-2.

    Time frame: Days 0-2

Secondary outcomes

  1. Rate of change in sputum log CFU/mL count (extended EBA).

    Time frame: Days 2-14

  2. Rate of change in sputum log CFU/mL count (extended EBA).

    Time frame: Days 0-14

  3. Rate of change in culture time to positivity (TTP) measured by MGIT and in log transformed TTP

    Time frame: Days 02-; 2-14; 0-14

  4. Cumulative whole blood bactericidal activity (measured as log reduction in CFU) against intracellular M. tuberculosis relative to administered dose and drug PK

    Time frame: Day 1

  5. Cumulative whole blood bactericidal activity (measured as log reduction in CFU) against intracellular M. tuberculosis relative to administered dose and drug PK

    Time frame: Day 13-14

  6. Plasma concentrations of PNU-100480 and PNU-101603 will be used to determine PK parameters (AUCtau, AUC tau,ss, Cmax, Tmax, terminal half-life t1/2, Cavg, Rac) as data permit

    Time frame: Day 1

  7. Plasma concentrations of PNU-100480 and PNU-101603 will be used to determine PK parameters (AUCtau, AUC tau,ss, Cmax, Tmax, terminal half-life t1/2, Cavg, Rac) as data permit

    Time frame: Day 13-14

  8. Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.

    Time frame: Phys exam, AEs, and vitals are done at every visit (Screening through Day 15, Day 42/Follow-up)

  9. Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.

    Time frame: ECGs are done at Screening, Day 1, Day 14, 15 and 42/Follow-up

  10. Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.

    Time frame: Lab tests at Screening, Day 1, Day 15 and 42/Follow-up

07

Study locations

2 sites
  • Pfizer Investigational Site
    Bellville, Cape Town 7530, South Africa
  • Pfizer Investigational Site
    Cape Town, 7700, South Africa
08

References and documents

Publications

  • Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014 Apr 14;9(4):e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014. PubMed 24732289 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2010
First posted
Oct 21, 2010
Start
Aug 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Mar 19, 2013
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01225640
Lead sponsor
Sequella, Inc.
Responsible party
Sponsor
First posted
Oct 21, 2010
Start date
Aug 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Jan 14, 2016

Study contacts

Lisa Beth Ferstenberg, M.D.
study director · Sequella, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PNU-100480

Start the discussion